Arix Bioscience PLC
LSE:ARIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Arix Bioscience PLC
LSE:ARIX
|
UK |
|
K
|
Kejuruteraan Asastera Bhd
KLSE:KRONO
|
MY |
Balance Sheet
Balance Sheet Decomposition
Arix Bioscience PLC
Arix Bioscience PLC
Balance Sheet
Arix Bioscience PLC
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
29
|
75
|
31
|
55
|
112
|
134
|
123
|
|
| Cash |
29
|
75
|
31
|
55
|
112
|
134
|
123
|
|
| Total Receivables |
3
|
1
|
2
|
1
|
1
|
2
|
2
|
|
| Accounts Receivables |
1
|
0
|
2
|
1
|
1
|
2
|
2
|
|
| Other Receivables |
3
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
61
|
0
|
63
|
0
|
0
|
|
| Total Current Assets |
32
|
76
|
93
|
56
|
176
|
136
|
125
|
|
| PP&E Net |
1
|
1
|
0
|
1
|
0
|
0
|
0
|
|
| PP&E Gross |
1
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
2
|
2
|
2
|
1
|
0
|
0
|
0
|
|
| Long-Term Investments |
17
|
71
|
184
|
152
|
155
|
121
|
103
|
|
| Total Assets |
52
N/A
|
150
+186%
|
280
+86%
|
209
-25%
|
331
+58%
|
257
-22%
|
228
-11%
|
|
| Liabilities | ||||||||
| Accounts Payable |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Accrued Liabilities |
4
|
3
|
3
|
6
|
2
|
2
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
6
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
6
|
4
|
9
|
6
|
2
|
2
|
2
|
|
| Long-Term Debt |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Total Liabilities |
6
N/A
|
4
-39%
|
9
+151%
|
7
-24%
|
3
-65%
|
2
-32%
|
2
+14%
|
|
| Equity | ||||||||
| Common Stock |
0
|
0
|
189
|
189
|
189
|
189
|
189
|
|
| Retained Earnings |
46
|
41
|
82
|
14
|
140
|
67
|
37
|
|
| Additional Paid In Capital |
0
|
105
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
46
N/A
|
146
+216%
|
270
+85%
|
202
-25%
|
328
+62%
|
255
-22%
|
226
-12%
|
|
| Total Liabilities & Equity |
52
N/A
|
150
+186%
|
280
+86%
|
209
-25%
|
331
+58%
|
257
-22%
|
228
-11%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
90
|
96
|
135
|
136
|
136
|
123
|
129
|
|